CRTX - Cortexyme outlines milestones for 2022

Cortexyme (NASDAQ:CRTX) provided a business update and announced key milestones for 2022. COR588 in mild to moderate Alzheimer’s Disease (AD): COR588 is currently completing a Phase 1 SAD/MAD trial in a cohort of healthy participants in Australia with study results expected in Q2 2022. Following the Phase 1 study, and subject to continued interactions with FDA, Cortexyme plans to advance COR588 to a Phase 2 trial to assess dose ranging, biomarker response, and further evaluate the safety profile. Atuzaginstat (COR388) in oncology for prevention of oral squamous cell carcinoma: The company held a pre-IND meeting with FDA and plans to submit an IND in Q1 2022. Atuzaginstat (COR388) in mild to moderate AD: Cortexyme intends to present additional analysis and insights from its extensive GAIN Trial data set at upcoming scientific meetings, including AD/PD 2022, the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, a hybrid event

For further details see:

Cortexyme outlines milestones for 2022